Liminatus Pharma, Inc. (LIMN)
3.78
+0.09
(+2.44%)
USD |
NASDAQ |
Oct 09, 16:00
3.78
0.00 (0.00%)
After-Hours: 20:00
Liminatus Pharma Debt to Equity Ratio : 4.799 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.799 |
| March 31, 2026 | -10.88 |
| December 31, 2025 | -0.147 |
| September 30, 2025 | -0.8765 |
| June 30, 2025 | -0.1638 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | -1.033 |
| September 30, 2024 | -0.3207 |
| June 30, 2024 | -0.2886 |
| March 31, 2024 | -0.3381 |
| December 31, 2023 | -0.2124 |
| September 30, 2023 | -0.1748 |
| Date | Value |
|---|---|
| June 30, 2023 | 2.437 |
| March 31, 2023 | 3.374 |
| December 31, 2022 | 0.8036 |
| September 30, 2022 | 0.0032 |
| June 30, 2022 | 0.0003 |
| March 31, 2022 | 0.0005 |
| December 31, 2021 | 0.0004 |
| September 30, 2021 | 0.0002 |
| June 30, 2021 | 0.0003 |
| March 31, 2021 | 0.0002 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 3.404M |
| Total Liabilities (Quarterly) | 3.103M |
| Shareholders Equity (Quarterly) | 0.3006M |
| Current Ratio | 1.116 |
| Net Debt Paydown Yield | -233.3% |